Generative AI drug creation company Absci Corporation announced on Wednesday a strategic collaboration with AMD to enhance its AI-driven drug discovery capabilities. Through this partnership, Absci will deploy AMD's Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including de novo antibody design models. As part of the partnership, AMD is making a USD 20 million investment in Absci via a private investment in public equity (PIPE), highlighting the "growing demand for AI in drug discovery," Absci said.
Also Read: Accenture Invests in 1910 Genetics to Accelerate AI-Driven Drug Discovery
AMD Investment Boosts Absci's AI Drug Discovery
"The strategic partnership supports Absci’s mission of creating better biologics for patients, faster by providing optimized AI solutions for complex biological modeling that offer exceptional performance, reduced infrastructure costs, and faster innovation cycles," the AI drug creation company said on January 8, 2025. The company noted that this partnership is expected to further expand biopharma adoption of AMD Instinct accelerators and ROCm software.
"This partnership with AMD gives us the unique advantage of working closely with a partner that is deeply committed to supporting our needs while providing the most efficient, innovative AI solutions available," said Sean McClain, Founder and CEO of Absci. "AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics, and we are excited about the potential that this partnership holds to accelerate the future of drug discovery."
Also Read: AI Can Transform Healthcare: Tata Sons Chairman
"We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics and transform how biologic drugs are developed," said Mark Papermaster, Executive Vice President and Chief Technology Officer of AMD.
"Absci's groundbreaking work in AI drug discovery is a perfect fit for AMD high-performance computing solutions and software, designed for the most demanding AI workloads," Papermaster added.
Absci and AMD to Showcase Performance
According to the official release, at the 43rd Annual J P Morgan Healthcare Conference on Wednesday, January 15th, "Absci and AMD will showcase the exceptional performance of AMD's Instinct accelerators in addressing complex biological applications, including Absci's proprietary IgDesign1 model, the first in vitro validated inverse folding model for antibody design."
